Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Shire, Allergan Move To Shore Up Core Franchises

Executive Summary

Bristol acquires Cardioxyl and its Phase II congestive heart failure candidate as the latest deal to firm up its specialty drug pipeline, while Sanofi inks a cancer immunotherapy deal with BioNTech and a pair of diabetes-related partnerships with Hanmi and Lexicon.

You may also be interested in...



Sanofi And Lexicon Fall Out Over Zynquista, As French Group Exits Diabetes Pact

Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes. 

Moderna CEO Bancel Pushes Back On Trump Debate Comments On COVID-19 Vaccine

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

Moderna CEO Pushes Back On Trump Debate Comments On COVID Vaccine, Offers Own Timeline

After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel